BiotechTube

Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + Leucovorin

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neoplasm Metastasis

Conditions

Neoplasm Metastasis, Colorectal Neoplasms, Breast Cancer

Trial Timeline

Jun 18, 2014 → Feb 13, 2020

NCT ID
NCT02124148

About Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + Leucovorin

Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + Leucovorin is a phase 1 stage product being developed by Eli Lilly for Neoplasm Metastasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02124148. Target conditions include Neoplasm Metastasis, Colorectal Neoplasms, Breast Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Neoplasm Metastasis were approved

Approved (20) Terminated (3) Active (0)
✅LenvatinibEisaiApproved
✅Eribulin mesylateEisaiApproved
✅Eribulin MesylateEisaiApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved
✅Chlorhydrate de RopivacaineAstraZenecaApproved
✅Sitagliptin + placeboMerckApproved
✅Palonosetron and DexamethasoneMerckApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02124148Phase 1Completed

Competing Products

20 competing products in Neoplasm Metastasis

See all competitors
ProductCompanyStageHype Score
ADC-1013Alligator Bioscience ABPhase 1
19
FulvestrantDr. Reddy's LaboratoriesPre-clinical
19
AB0024Gilead SciencesPhase 1
29
TTI-237PfizerPhase 1
21
852APfizerPhase 1
29
EO-3021 + Ramucirumab (CYRAMZA®) + DostarlimabCSPC Pharmaceutical Group LimitedPhase 1
21
LY2780301Eli LillyPhase 1
29
PemetrexedEli LillyPhase 2
35
pemetrexed + cisplatinEli LillyPhase 1/2
32
IMC-3C5Eli LillyPhase 1
29
LY3295668Eli LillyPhase 1/2
32
Abemaciclib + ClarithromycinEli LillyPhase 1
29
Abemaciclib + FulvestrantEli LillyPhase 2
27
Galunisertib + Gemcitabine + PlaceboEli LillyPhase 1/2
32
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
44
LY2784544Eli LillyPhase 1
29
Tadalafil + GemcitabineEli LillyPhase 1
29
enzastaurinEli LillyPhase 2
35
enzastaurin + gemcitabineEli LillyPhase 2
35